Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

AG-636 for the Treatment of Adults with Advanced Lymphoma: Initiation of a Phase 1 Clinical Study

Scott F. Huntington, MD MPH, Avyakta Kallam, MD, Frank G. Basile, MD, Danielle Ulanet, Huansheng Xu, PhD, Feng Yin, PhD, Michelle Mobilia, BS, Michael Cooper, MD, Bijal Shah, MD, John P. Leonard, MD, Gottfried R. von Keudell, MD PhD, Ajay K. Gopal, MD

Blood (2019) 134 (Supplement_1): 1286.

https://doi.org/10.1182/blood-2019-123420

Published: 2019

Journal Articles

Hematologic Malignancies Exhibit Selective Vulnerability to Inhibition of De Novo Pyrimidine Biosynthesis By AG-636, a Novel Inhibitor of Dihydroorotate Dehydrogenase in Phase 1 Clinical Trials

Danielle Ulanet, Victor Chubukov, PhD, John Coco, BS, Gabrielle McDonald, PhD, Mya Steadman, BA, Rohini Narayanaswamy, MS, Sebastien Ronseaux, PhD, Sung Choe, PhD, Tabea Erdmann, PhD, Kevin Truskowski, BS, Kavitha Nellore, PhD, Siva Sanjeeva Rao, PhD, Hosahalli Subramanya, PhD, Georg Lenz, MD, Michael Cooper, MD, Josh Murtie, PhD, Kevin Marks, PhD

Blood (2019) 134 (Supplement_1): 1570.

https://doi.org/10.1182/blood-2019-123471

Published: 2019

Journal Articles

Bone Marrow Morphologic Findings in Patients Receiving IDH Inhibitor Therapy in Combination with Intensive Induction Chemotherapy: Challenges with Interpretation of the Day 14 Bone Marrow Biopsy

Emily F Mason, MD PhD, Olga Pozdnyakova, MD PhD, Mikhail Roshal, MD PhD, Amir T. Fathi, MD, Eytan M. Stein, MD, Aaron C. Shaver, MD PhD, Mark G. Frattini, MD, Hongfang Wang, PhD, Lei Hua, PhD, Jimmy Mu, Caroline Almon, MS, Michael Cooper, MD, Richard M. Stone, MD, Robert P. Hasserjian, MD, Michael R. Savona, MD

Blood (2019) 134 (Supplement_1): 1442.

https://doi.org/10.1182/blood-2019-123845

Published: 2019

Journal Articles

Ivosidenib or Enasidenib Combined with Induction and Consolidation Chemotherapy in Patients with Newly Diagnosed AML with an IDH1 or IDH2 Mutation Is Safe, Effective, and Leads to MRD-Negative Complete Remissions

Blood (2018) 132 (Supplement 1): 560.

https://doi.org/10.1182/blood-2018-99-110449

Published: 2018

Journal Articles

Ivosidenib or Enasidenib Combined with Standard Induction Chemotherapy Is Well Tolerated and Active in Patients with Newly Diagnosed AML with an IDH1 or IDH2 Mutation: Initial Results from a Phase 1 Trial

Eytan M. Stein, MD, Courtney D. DiNardo, MDMSc, Alice S. Mims, MD MSCR, Michael R. Savona, MD, Keith Pratz, MD, Anthony S. Stein, MD, Amir T. Fathi, MD MD BS, Richard M. Stone, MD, Daniel A. Pollyea, MD, Olatoyosi Odenike, MD, Bob Lowenberg, MD PhD, Hartmut Döhner, MD, Gary J. Schiller, Ira V. Gupta, MD, Salah Nabhan, Vickie Zhang, PhD, Caroline Almon, MS, Michael Cooper, MD, Martin S. Tallman, MD

Blood (2017) 130 (Supplement 1): 726.

https://doi.org/10.1182/blood.V130.Suppl_1.726.726

Published: 2017

Journal Articles

Concomitant Suppression of IKZF1, IRF4 and MYC Contribute to the Anti-Tumor Activity of the BET Inhibitor, Cpi-0610, in Disease Models of Multiple Myeloma

Ka Tat Siu, PhD, Janani Ramachandran, MA, Andrew J. Yee, MD, Homare Eda, MD PhD, Loredana Santo, MD, Elizabeth K. O'Donnell, MD, Cristina Panaroni, PhD, Jennifer Mertz, PhD, Robert J. Sims, PhD, Michael Cooper, MD, Noopur Raje, MD

Blood (2016) 128 (22): 3320.

https://doi.org/10.1182/blood.V128.22.3320.3320

Published: 2016

Journal Articles

Effect of the BET Inhibitor, Cpi-0610, Alone and in Combination with Lenalidomide in Multiple Myeloma

Ka Tat Siu, PhD, Homare Eda, MDPhD, Loredana Santo, MD, Janani Ramachandran, MA, Miroslav Koulnis, PhD, Jennifer Mertz, PhD, Robert J. Sims, PhD, Michael Cooper, MD, Noopur S. Raje, MD

Blood (2015) 126 (23): 4255.

https://doi.org/10.1182/blood.V126.23.4255.4255

Published: 2015

Journal Articles

BET Inhibitor CPI-0610 Is Well Tolerated and Induces Responses in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma: Preliminary Analysis of an Ongoing Phase 1 Study

Jeremy S. Abramson, MD, Kristie A. Blum, MD, Ian W. Flinn, MD PhD, Martin Gutierrez, MD, Andre Goy, MD, Michael Maris, MD, Michael Cooper, MD, Michael O'Meara, MS, Darrell Borger, PhD, Jennifer Mertz, PhD, Robert J. Sims, PhD, Supko Jeffrey, PhD, Anas Younes, MD

Blood (2015) 126 (23): 1491.

https://doi.org/10.1182/blood.V126.23.1491.1491

Published: 2015

Journal Articles

Development of BET Protein Bromodomain Inhibition for the Treatment of Hematologic Malignancies

Robert Sims, PhD, Emmanuel Normant, PharmD, PhD, Peter Sandy, PhD, Jennifer Mertz, PhD, Barbara Bryant, PhD, Michael O'Meara, MS, Marie Green, PhD, Michael Cooper, MD, Jim Audia, PhD

Blood (2012) 120 (21): 1331.

https://doi.org/10.1182/blood.V120.21.1331.1331

Published: 2012

Journal Articles

Phase 1/2 Study of Tandutinib (MLN518) Plus Standard Induction Chemotherapy in Newly Diagnosed Acute Myelogenous Leukemia (AML).

Daniel J. DeAngelo, MD, PhD, Philip C. Amrein, MD, Tibor J. Kovacsovics, MD, Rebecca B. Klisovic, Bayard L. Powell, MD, Michael Cooper, MD, Iain J. Webb, Richard M. Stone, MD

Blood (2006) 108 (11): 158.

https://doi.org/10.1182/blood.V108.11.158.158

Published: 2006

NARROW

AG-636 for the Treatment of Adults with Advanced Lymphoma: Initiation of a Phase 1 Clinical Study

Hematologic Malignancies Exhibit Selective Vulnerability to Inhibition of De Novo Pyrimidine Biosynthesis By AG-636, a Novel Inhibitor of Dihydroorotate Dehydrogenase in Phase 1 Clinical Trials

Bone Marrow Morphologic Findings in Patients Receiving IDH Inhibitor Therapy in Combination with Intensive Induction Chemotherapy: Challenges with Interpretation of the Day 14 Bone Marrow Biopsy

Ivosidenib or Enasidenib Combined with Induction and Consolidation Chemotherapy in Patients with Newly Diagnosed AML with an IDH1 or IDH2 Mutation Is Safe, Effective, and Leads to MRD-Negative Complete Remissions

Ivosidenib or Enasidenib Combined with Standard Induction Chemotherapy Is Well Tolerated and Active in Patients with Newly Diagnosed AML with an IDH1 or IDH2 Mutation: Initial Results from a Phase 1 Trial

Concomitant Suppression of IKZF1, IRF4 and MYC Contribute to the Anti-Tumor Activity of the BET Inhibitor, Cpi-0610, in Disease Models of Multiple Myeloma

Effect of the BET Inhibitor, Cpi-0610, Alone and in Combination with Lenalidomide in Multiple Myeloma

BET Inhibitor CPI-0610 Is Well Tolerated and Induces Responses in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma: Preliminary Analysis of an Ongoing Phase 1 Study

Development of BET Protein Bromodomain Inhibition for the Treatment of Hematologic Malignancies

Phase 1/2 Study of Tandutinib (MLN518) Plus Standard Induction Chemotherapy in Newly Diagnosed Acute Myelogenous Leukemia (AML).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only